

Initial Prior Authorization Nail Antifungal, Topical

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
Jublia	efinaconazole	topical solution
Kerydin	tavaborole	topical solution

Indications

FDA-approved Indications

Jublia

Jublia (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

Kerydin

Kerydin (tavaborole) topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*.

Coverage Criteria

Onychomycosis of the Toenail(s)

Reference number(s)
1325-A

Authorization may be granted when the requested drug is being prescribed for onychomycosis of the toenail(s) due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* when the following criteria is met:

- The patient's diagnosis has been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy).

Duration of Approval (DOA)

- 1325-A: DOA: 12 months

References

1. Jublia [package insert]. Bridgewater, NJ: Bausch Health US LLC; July 2025.
2. Kerydin [package insert]. Melville, NY: Fougera Pharmaceuticals Inc.; August 2018.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed August 26, 2025.
4. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/26/2025).
5. Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. American Academy of Family Physicians. 2021;104:359-367.